Barcelona

• A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genet … Recruiting
  2024-513300-34-00 1 2024-11-18 Advanced solid tumors harboring KRAS G12C mutation
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting
  2023-505232-36-00 5 2024-11-15 Essential thrombocythemia
• MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting
  2023-507776-42-00 5 2024-11-14 Non-small cell lung cancer
• A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting
  2023-509230-19-00 7 2024-11-14 Advance solid tumors
• Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting
  2024-513098-31-00 4 2024-11-14 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
• Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors Recruiting
  2024-516011-24-01 4 2024-11-13 Cytomegalovirus infection in allogeneic stem cell transplant recipient
• A study of AZD0901 alone or in combination with other anticancer drugs in patients with advanced/metastatic cancer. Recruiting
  2023-508275-37-00 9 2024-11-11 Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Ad
• A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxeta … Recruiting
  2024-512338-13-00 3 2024-11-11 Metastatic Castration-Resistant Prostate Cancer
• A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe … Recruiting
  2023-508517-16-00 7 2024-11-10 Advanced Solid Tumors with a KRAS p.G12C Mutation
• LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Pa … Recruiting
  2023-507178-41-00 9 2024-11-07 Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 Advanced PRAME Positive Cancers
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie … Recruiting
  2023-505242-25-00 4 2024-11-05 High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-Hig
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04 Triple negative breast cancer
• A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia Recruiting
  2023-510288-37-00 3 2024-11-01 Relapsed and/or refractory Acute Myeloid Leukemia
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re … Recruiting
  2022-502972-22-00 5 2024-10-31 Clostridioides difficile infection.
• Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo … Recruiting
  2024-516777-77-00 4 2024-10-31 Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GE
• Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects … Recruiting
  2023-505334-10-01 7 2024-10-30 Unresectable, Locally Advanced, or Metastatic Solid Tumors
• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies Recruiting
  2024-511453-22-00 1 2024-10-28 Participants with Advanced Solid Malignancies
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi … Recruiting
  2023-509851-15-00 5 2024-10-22 Colon cancer
• Beamion PANTUMOR-1: A study to test whether zongertinib helps people with advanced cancers with HER2 alterations Recruiting
  2023-510429-14-00 4 2024-10-22 HER2-mutated or overexpressed/amplified solid tumours

Showing 1,201–1,224 of 3,391 trials